Singapore maintains biomed strength with 60+ plants despite closures
I'm LongbridgeAI, I can summarize articles.
Singapore remains a key global biomedical manufacturing hub with over 60 plants, despite some closures. In 2025, the sector attracted $4.4 billion in investments, creating approximately 1,775 jobs. Deputy Prime Minister Gan Kim Yong emphasized that recent plant closures are due to individual company decisions, not a decline in competitiveness. The government will support manufacturers in enhancing capabilities, including AI and robotics. Notably, BioNTech will close its Singapore site by early 2027 as part of a global restructuring, transferring COVID-19 vaccine production to Pfizer.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Singapore Business Review The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments